Comparing Clover Health Investments (NASDAQ:CLOV) & SOPHiA GENETICS (NASDAQ:SOPH)

SOPHiA GENETICS (NASDAQ:SOPH) and Clover Health Investments (NASDAQ:CLOV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Volatility and Risk

SOPHiA GENETICS has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Clover Health Investments has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500.

Profitability

This table compares SOPHiA GENETICS and Clover Health Investments’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-41.13%	-37.75%	-18.75%
Clover Health Investments	-3.29%	-16.79%	-9.95%

Insider & Institutional Ownership

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 19.8% of Clover Health Investments shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 24.1% of Clover Health Investments shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for SOPHiA GENETICS and Clover Health Investments, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1	0	1	0	2.00
Clover Health Investments	1	3	1	0	2.00

SOPHiA GENETICS presently has a consensus price target of $7.00, indicating a potential upside of 32.33%. Clover Health Investments has a consensus price target of $3.23, indicating a potential upside of 24.36%. Given SOPHiA GENETICS’s higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Clover Health Investments.

Earnings and Valuation

This table compares SOPHiA GENETICS and Clover Health Investments”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$65.17 million	5.49	-$62.49 million	($0.46)	-11.50
Clover Health Investments	$1.37 billion	0.98	-$43.01 million	($0.11)	-23.64

Clover Health Investments has higher revenue and earnings than SOPHiA GENETICS. Clover Health Investments is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Summary

Clover Health Investments beats SOPHiA GENETICS on 8 of the 12 factors compared between the two stocks.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.